Alexis, Andrew F.
Gooderham, Melinda
Kwatra, Shawn G.
Amin, Ahmad
Taylor, Susan
Espaillat, Ramon
Rettig, Trisha
Wu, Tianshuang
Shi, Linyu
Kaldas, Mark I.
Dilley, Deanne M.
Sinvhal, Ranjeeta
Nduaka, Chudy
Lockshin, Benjamin
Funding for this research was provided by:
AbbVie
Article History
Received: 13 July 2024
Accepted: 29 August 2024
First Online: 2 October 2024
Declarations
:
: A Alexis has received grants from Leo, Amgen, Galderma, Arcutis, Dermavant, AbbVie, and Castle, has served on advisory boards or as an consultant for Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Ortho, L’Oreal, BMS, Bausch health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, AbbVie, Amgen, VisualDx, Eli Lilly, Swiss American, Cutera, Cara, EPI, Incyte, Castle, Apogee, Canfield, and Alphyn, has received speaker fees from Regeneron, SANOFI-Genzyme, BMS, L’Oreal, Janssen, and J&J, has received royalties from Springer, Wiley-Blackwell, and Wolters Kluwer Health and has received an equipment loan from Aerolase. M Gooderham has received speaker or consulting fees and/or research grants from: AbbVie, Amgen, Akros, Aslan, AnaptysBio, Aristea, Arcutis, Bausch Health, BMS, Boehringer Ingelheim, Cara Therapeutics, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Mooklake, Meiji, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, UCB. S G Kwatra has received speaker or consulting fees and/or research grants AbbVie, Celldex Therapeutics, Galderma, Incyte Corporation, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals and has served as an investigator for Galderma, Kiniksa Pharmaceuticals, Pfizer Inc., and Sanofi. A Amin has received speaker or consulting fees from AbbVie, Eli Lilly, Janssen, Dermavant, Leo Pharma, Regeneron, Sanofi/Genzyme, UCB, Amgen, BMS, and Pfizer. S Taylor has served on advisory boards for AbbVie, Avita Medical, Beiersdorf, Eli Lilly, EPI Health, Evolus, Galderma, Hugel, Incyte, Johnson & Johnson, L’Oreal, Medscape, Pfizer, Scientis, UCB and Vichy Laboratories, has served as an investigator for Allergan, Concert Pharamceuticals, Croma-Pharma GmbH Austria, Eli Lilly, Pfizer, and Sun Pharma, has served as a constulta form Armis Biopharma, Beiersdof, Bristol-Meyers Squibb, Cara Therapeutics, Dior, GloGetter, Piction Health, and Sanofi, has received speaker fees for Beiersdort, Catalyst Medical Education, Medscape, and MJH Life Sciences, and serves on the board of directors and has received employee fees from Mercer Strategies. R Espaillat, T Rettig, M Kaldas, T Wu, L Shi, DM Dilley, R Sinvhal, and C Nduaka are full-time salaried employees of AbbVie and may own stock/options. B Lockshin has received speaker and/or consulting fees and/or research grants from AbbVie, Novartis, Eli Lilly, Sanofi, Regeneron, Incyte, Leo, UCB, DermTech, Strata Skin Sciences, Corrona Registry, Boehringer Ingelheim, Pfizer, Franklin Bioscience, Trevi Therapeutics, Inc., Vanda, Celgene, Galderma, Amgen, and Dermira.
: The LIMMitless study is being conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonisation, the Declaration of Helsinki and/or all applicable federal and local regulations, and all patients provided written informed consent. All protocols were approved by an institutional review board (Quorom Review IRB, Seattle, WA, USA).